3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Leukemia, Myeloid, Acute
4
Breast Neoplasms
4
Lung Neoplasms
3
Neoplasm Metastasis
2
Tissue Adhesions
1
Solid Tumor Refractory to Standard Therapy
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Platinum Resistant Ovarian Cancer
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Ototoxicity
1
Neutropenia
1
Neoplasms
1
Myoma
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphopenia
1
Locally Advanced Cervical Cancer
1
Limited Stage Small Cell Lung Cancer
1
Leiomyoma
1
Hearing Loss
1
Febrile Neutropenia
1
Fatigue
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
36
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
19
Papillomavirus Vaccines
16
Vaccines
10
Data Collection
9
Blood Specimen Collection
5
Vaccines, Synthetic
4
artesunic acid
3
artemisinin
3
Engerix-B
3
halofantrine
2
epigallocatechin gallate
2
artenimol
2
Hepatitis A Vaccines
2
GX-188 vaccine
2
Colposcopy
2
ranpirnase
1
fludarabine
1
Viusid
1
Vitamin B 12
1
VP-102
1
VGX-3100
1
Therapies, Investigational
1
Sodium Chloride
1
Pentetic Acid
1
Observation
1
Methods
1
Measles-Mumps-Rubella Vaccine
1
Interleukin-2
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Papillomavirus Infections
×
Sodium Chloride
×
Clear all
NCT04199689
2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
6,033 enrolled